<DOC>
	<DOC>NCT01200784</DOC>
	<brief_summary>Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.</brief_summary>
	<brief_title>Nicotinamide in Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>hemodialysis since 3 months or longer hemodialysis frequency 3 times weekly stable phosphate binder dose since one month at screening serum phosphate level &lt; 2,42 mmol/l at screening serum phosphate level &gt; 1,52 mmol/l after wash out phase stable treatment with vitamin D analogues since one month at screening congestive heart failure acute bleeding complications acute myocardial infarction peptic ulcers serious liver damage poorly controlled diabetes severe visual impairment uncontrolled high blood pressure thrombocyte count &lt; 120/nl difficulties in swallowing or dysphagia diminished intestinal motility, megacolon, pseudo or mechanical obstruction gastroparesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>